TORONTO, January 25, 2021,10:00 ET – Geneseeq Technology Inc. (“Geneseeq”), along with our clinical collaborators will be presenting new data at the 2020 IASLC World Conference on Lung Cancer in Singapore, commencing on January 28 to January 31, 2021. During the conference, we will be presenting our studies via two mini oral presentations and four poster presentations covering the topics of the genomic evolution and immune microenvironments in metastatic lung cancer, lung cancer molecular biomarker expression predictions, age-dependent genomic landscape of lung cancer patients, EGFR-TKI resistant mechanism through BRAF activation, genomic and immunological characteristics in lung adenocarcinoma with micropapillary component and the sensitivity of rare EGFR mutations to TKIs. The presentation materials will be available virtually. For any further inquiries related to our product and services, please contact partnership.toronto@geneseeq.com.

Highlights of our studies include:

  • By employing multi-region whole-exome sequencing and immunohistochemistry in 179 samples from 51 lung cancer patients, the data revealed differences in genomic landscapes, molecular determinants, seeding patterns, and lymphocyte infiltration among different metastatic sites. (Mini oral MA14.09)
  • This study highlighted the association between PD-L1 expression and genomic features, and identified predictive biomarkers for PD-L1 expression level when IHC analysis is not available. (Mini oral MA08.06)
  • The investigation of age-dependent tendency of genomic alterations in lung cancer, and examination of mutational profiles and its association with clinical treatment outcomes in young adenocarcinoma patients, by studying 7,858 lung cancer samples using targeted-gene sequencing. (Poster35.23)
  • Tumors with a higher percentage of micropapillary component (MPC) tended to harbor high tumor mutation burden (TMB) and increased chromosome instability (CIN). Some rare genetic events may serve as genetic landscape driving micropapillary tumor progression. (Poster 35.23)
  • Combination therapy of BRAF/MEK inhibitors and EGFR TKIs showed promising anti-tumor activity in EGFR-TKI resistant patients with BRAF (Poster 76.90)
  • EGFR L747 mutations account for ~0.4% in EGFR-mutated NSCLC patients. EGFR L747P might exert superior sensitivity to afatinib treatment, while both EGFR L747P and L747S displayed poor response to first-generation EGFR TKI. (Poster 76.40)

The following is the full list of our presentations and posters. To access full abstracts for more details, please visit https://library.iaslc.org/conference-program?product_id=20.

Category Presentation/Poster ID Title Date & Time
Mini Oral MA08.06 Stratifying PD-L1 expression level based on multimodal genomic features for the prediction of immunotherapy benefit in NSCLC 1/30

17:00-17:05 SGT
Mini Oral MA13.09 Heterogeneous Genomic Evolution and Immune Microenvironments in Metastatic Lung Cancer. 1/31

17:30-17:35 SGT
Poster P35.23 Integrated analysis of genomic and immunological features in lung adenocarcinoma with micropapillary component 1/28 ePoster Hall
Poster P76.90 Molecular Characteristics of BRAF Activating Mutations in EGFR Mutant NSCLC Patients after Progression on EGFR TKIs and Response to Combined BRAF/MEK Inhibitors and EGFR TKIs. 1/28 ePoster Hall
Poster P35.29 The genomic landscape of lung cancer patients highlights age-dependent mutation frequencies and clinical actionability in young patients 1/28 ePoster Hall
Poster P76.40 Molecular Characteristics and Response to EGFR TKIs of EGFR L747 Position Mutation in Lung Cancer Patients 1/28 ePoster Hall

About Geneseeq

Geneseeq is a research-driven company providing cutting-edge NGS technology to accelerate precision cancer care. We offer both pan-cancer panels analyzing 400+ genes and cancer-type specific gene panels to help match patients to optimal treatments, including targeted therapy and immunotherapy. We have 1000+ research projects with biopharma and research partners, providing high-quality genomic data to accelerate translational research. Our headquarters are located in Canada and China. Our CAP/CLIA-accredited Chinese site is equipped with multiple advanced NGS sequencing platforms and has sequenced 400,000+ clinical samples. For more information, please visit na.geneseeq.com or follow Geneseeq on Linkedin and Twitter.